Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2008 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R. Bullock R. Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. doi: 10.1097/01.wad.0000201847.29836.a5. Alzheimer Dis Assoc Disord. 2006. PMID: 16493232 Review.
Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, is currently the only agent approved for moderately severe to severe Alzheimer disease (AD) in Europe and for moderate-to-severe Alzheimer d …
Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, is currently the only agent approved for mode …
Memantine for dementia.
Areosa Sastre A, McShane R, Sherriff F. Areosa Sastre A, et al. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. doi: 10.1002/14651858.CD003154.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154. doi: 10.1002/14651858.CD003154.pub3. PMID: 15495043 Updated. Review.
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease, or vascular or mixed dementia. ...This suggests that, in patients with mild to moderate vascular dementia, the effect on cognitive functi …
OBJECTIVES: To determine the clinical efficacy and safety of memantine for people with Alzheimer's disease …
Memantine for dementia.
Areosa SA, Sherriff F. Areosa SA, et al. Cochrane Database Syst Rev. 2003;(3):CD003154. doi: 10.1002/14651858.CD003154. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003154. doi: 10.1002/14651858.CD003154.pub2. PMID: 12917950 Updated. Review.
REVIEWER'S CONCLUSIONS: There is a beneficial effect of memantine (20 mg/day) for patients with moderate to severe Alzheimer disease on cognition and functional decline but not in the clinical impression of change. Patifor patients with …
REVIEWER'S CONCLUSIONS: There is a beneficial effect of memantine (20 mg/day) for patients with moderate to severe …
[Antidementia drugs--response or non-response?].
Förstl H. Förstl H. Internist (Berl). 2008 Mar;49(3):353-9. doi: 10.1007/s00108-007-1990-y. Internist (Berl). 2008. PMID: 18210027 German.
Constructs which are valid for research projects become misnomers in clinical practice. To date there are two groups of antidementia drugs, memantine--an NMDA-receptor modulator licensed for the moderate to severe stages--and the cholinesterase …
Constructs which are valid for research projects become misnomers in clinical practice. To date there are two groups of antidementia …